Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423755 | 1.00 | GRM2 (0.61) | GRM2 | |
| SCHEMBL22949599 | 0.88 | GRM2 (0.48) | GRM2 | |
| SCHEMBL17485488 | 0.86 | GRM2 (0.60) | GRM2 | |
| SCHEMBL17480539 | 0.86 | GRM2 (0.68) | GRM2 | |
| SCHEMBL17485545 | 0.84 | GRM2 (0.67) | GRM2 | |
| SCHEMBL19195678 | 0.83 | GRM2 (0.61) | GRM2 | |
| SCHEMBL17485546 | 0.82 | GRM2 (0.61) | GRM2 | |
| SCHEMBL17485489 | 0.81 | GRM2 (0.68) | GRM2 | |
| SCHEMBL17699059 | 0.80 | GRM2 (0.80) | GRM2 | |
| SCHEMBL16402672 | 0.80 | GRM2 (0.80) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12150941-B2 | Process for preparing substituted pyrazolo[1,5-a]pyrazines | Sumitomo Pharma Co., Ltd. (JP) | 2024-11-26 | — | — | US | disclosed |
| EP-3719023-B1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | SUMITOMO PHARMA CO LTD (JP) | 2024-10-16 | — | — | EP | disclosed |
| US-20230210850-A1 | PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230210850-A1 | PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230210850-A1 | PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-06 | — | — | US | disclosed |
| CN-111601811-B | 6, 7-dihydropyrazolo [1,5-a ] pyrazinone derivatives and medical uses thereof | 住友制药株式会社 | 2023-05-05 | — | — | CN | disclosed |
| US-11633395-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-10953008-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-03-23 | — | — | US | disclosed |
| US-10953008-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20210030754-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20210030754-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20200345729-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3719023-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL APPLICATION THEREOF | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| CN-111601811-A | 6, 7-dihydropyrazolo [1,5-a ] pyrazinone derivatives and their pharmaceutical use | 大日本住友制药株式会社 | 2020-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210850-A1 | PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES | CYP3A5, CYP2F1, CYP4Z1 | GRM2 3682/4885 |
| US-20200345729-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | GRM5, GRM6, GRM2 | GRM2 3/4885 |
| US-12150941-B2 | Process for preparing substituted pyrazolo[1,5-a]pyrazines | CYP3A5, CYP2F1, CYP4Z1 | GRM2 3682/4885 |
| US-10953008-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor | GRM5, GRM1, GRM2 | GRM2 3/4885 |
| US-20210030754-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | GRM5, GRM6, GRM2 | GRM2 3/4885 |
| US-11633395-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor | GRM5, GRM1, GRM2 | GRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.